DexCom price target raised to $86 from $82 at Bernstein

Bernstein analyst Lee Hambright raised the firm’s price target on DexCom (DXCM) to $86 from $82 and keeps an Outperform rating on the shares. DexCom reported an in line quarter for Q3 and maintained its guidance for FY24, with global new customer starts returning to record levels, the analyst tells investors in a research note. There was significant uncertainty coming into Q3, and while no one is thrilled with 3% organic growth in Q3, the company made progress toward getting back on track, Bernstein says, and the firm sees more upside than downside in 2025.